<DOC>
	<DOCNO>NCT02520518</DOCNO>
	<brief_summary>Th mechanism action dapagliflozin via sodium-glucose co-transporter 2 ( SGLT2 ) inhibition . Sodium-glucose co-transporter 2 inhibition associate moderate weight ( fat ) loss , addition health benefit , include decrease blood pressure , decrease inflammation , decrease oxidative stress . It unclear whether health benefit due SGLT2 inhibition per se , secondary effect weight loss .</brief_summary>
	<brief_title>Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss ?</brief_title>
	<detailed_description>This randomize , prospective , placebo-controlled , double-blind , repeated measure study . 92 overweight/obese adult ( body mas index &gt; 27.5 kg/m^2 ) recruit participation randomly assign one four 12 week treatment : 1 ) daily oral administration dapagliflozin ad-libitum dietary intake ; 2 ) daily oral administration dapagliflozin supplement dietary intake achieve weight maintenance ; 3 ) daily oral administration placebo plus dietary restriction weight loss match participant treatment 1 ; , 4 ) daily oral administration placebo ad-libitum dietary intake .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedure . 2 . Aged 1865 year . 3 . No known Type 2 Diabetes 4 . Body mass index great equal 27.5 kg/m^2 5 . Sedentary ( maximum 2/week regularly schedule activity session &lt; 20 minute previous 2 year ) 6 . Completion screen visit consist medical history , physical examination , 12lead electrocardiogram blood pressure assessment rest incremental exercise volitional exhaustion ( Note : Subjects abnormal screen value may eligible result clinically significant , judged investigator medical monitor ) 7 . Agree abide study schedule dietary restriction return require assessment 8 . Women childbearing potential must negative pregnancy test use acceptable contraception 1 . Evidence clinically significant cardiovascular , respiratory , renal , hepatic , pulmonary , gastrointestinal , haematological , neurological , psychiatric , disease may interfere objective study safety subject , judge investigator agreement sponsor medical monitor , hospitalize past 2 year result condition , receive pharmacological treatment condition 2 . Use prescription drug ( see exception list ) herbal preparation 4 week study commencement . Permitted Prescription Drugs Birth Control Less 7 day , short course antibiotic . Note : Rifampin permit . Other medicine , Gastroesophageal Reflux Disease ( GERD ) , depression , seasonal allergy overthecounter analgesic , maybe allow , approve casebycase basis . 3 . Is currently enrol another clinical study another investigational drug take investigational drug within 30 day screen visit . 4 . Habitual and/or recent use ( within 2 year ) tobacco 5 . Being consider unsuitable participation trial reason , judge investigator medical monitor . 6 . History serious hypersensitivity reaction dapagliflozin 7 . Severe renal impairment , endstage renal disease , dialysis 8 . Pregnant breastfeeding patient 9 . Severe hepatic insufficiency and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal and/or alanine aminotransferase ( ALT ) &gt; 3x upper limit normal 10 . Total bilirubin &gt; 2.0 mg/dL ( 34.2 umol/L ) 11 . Positive serologic evidence current infectious liver disease include Hepatitis B viral antibody Immunoglobulin M , Hepatitis B surface antigen Hepatitis C virus antibody 12 . Estimated Glomerular Filtration Rate &lt; 60 mL/min/1.73 m^2 ( calculate CockcroftGault formula ) . 13 . History bladder cancer 14 . Recent cardiovascular event patient , include follow : acute coronary syndrome within 2 month prior enrollment ; hospitalization unstable angina acute myocardial infarction within 2 month prior enrollment ; acute stroke transischemic attack within two month prior enrollment ; le two month post coronary artery revascularization ; congestive heart failure define New York Heart Association class IV , unstable acute congestive heart failure . Note : eligible patient congestive heart failure , especially diuretic therapy , careful monitoring volume status throughout study 15 . Blood pressure enrolment : Systolic blood pressure ≥165 mmHg and/or diastolic blood pressure ≥100 mmHg 16 . Blood pressure randomization : Systolic blood pressure ≥165 mmHg and/or diastolic blood pressure ≥100 mmHg 17 . Patients , judgment medical monitor , may risk dehydration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>